share_log

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $70

Benzinga ·  Jun 1, 2023 07:13

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $67 to $70.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment